Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (NASDAQ: CERT) is a software‑driven company in the model‑informed drug development and biosimulation space. The CERT news page on Stock Titan aggregates company‑specific headlines so readers can follow how Certara’s biosimulation software, technology, and services are discussed in earnings releases, product announcements, scientific updates, and corporate events.
Recent Certara news highlights several recurring themes. The company issues quarterly financial results that describe revenue from biosimulation software and services, bookings trends, and updates to its full‑year financial outlook. These results are typically accompanied by commentary on demand for model‑informed drug development solutions and the performance of its software and services portfolio.
Certara also regularly announces new software capabilities and platform enhancements. Examples in recent releases include the launch of Certara IQ, an AI‑powered quantitative systems pharmacology solution, and TFL Studio, the first cloud‑native module of its Phoenix Cloud platform for pharmacokinetic and pharmacodynamic workflows. The company has additionally introduced Pinnacle 21 Enterprise Plus for managing CDISC SDTM and ADaM data specifications used in regulatory submissions.
Another category of news involves scientific recognition and research output, such as announcements about Certara scientists being listed among highly cited researchers and the publication of hundreds of scientific papers in a year. Corporate governance and leadership updates, including changes in the chief executive officer role, appear in both press releases and related SEC filings.
Investors, analysts, and industry professionals can use this news feed to monitor Certara’s financial disclosures, product roadmap, scientific contributions, and capital markets activity over time.
Certara, Inc. (Nasdaq: CERT) reported that 2020 was the seventh consecutive year where 90% of new drug and biologic approvals by the FDA were by its customers. In total, the FDA approved 54 new medicines in 2020, many of which received orphan and breakthrough designations. Certara’s biosimulation platforms, including Simcyp™, Phoenix™, and GlobalSubmit™, have been pivotal for drug development, enabling the provision of drug label claims without extensive clinical studies. CEO William Feehery highlighted the company's role in transforming drug development through advanced modeling techniques.
Certara, Inc. (Nasdaq: CERT) will announce its preliminary financial results for Q4 and the full year of 2020 post-market on March 4, 2021. A conference call to discuss these results will take place at 5:00 p.m. ET, accessible to investors through specific dialing options and a live webcast. Certara specializes in biosimulation technologies for drug discovery and development, serving over 1,650 biopharmaceutical companies and regulatory agencies in 61 countries.
Certara, a leader in biosimulation, announced the launch of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator. This version includes new models for maternal health, virtual bioequivalence, and long-acting injectable drugs. The simulator has informed the FDA approval of over 75 drugs, enhancing clinical trial efficiency. The expanded Simcyp Biologics Simulator aids in predicting pharmacokinetics for biologic drugs, crucial for their development. This software is pivotal for optimizing drug safety and efficacy in a vibrant biopharmaceutical R&D landscape.
Certara, a global leader in biosimulation, announced the closing of its upsized IPO on December 15, 2020, selling 33,413,250 shares at $23.00 each, raising approximately $336.5 million. Out of this, Certara itself sold 14,630,000 shares while certain stockholders sold 18,783,250 shares. Shares started trading on Nasdaq under the ticker symbol 'CERT' on December 11, 2020. The underwriters included Jefferies, Morgan Stanley, and BofA Securities, among others. This offering was registered under an effective Form S-1 with the Securities and Exchange Commission.
Certara has priced its upsized initial public offering (IPO) of 29,055,000 shares of common stock at $23.00 per share, aiming to raise approximately $336.5 million before expenses. The offering, scheduled to close on December 15, 2020, involves 14,630,000 shares from Certara and 14,425,000 from selling stockholders. Shares will trade on Nasdaq under the ticker 'CERT' starting December 11, 2020. A 30-day option for underwriters to purchase an additional 4,358,250 shares is also part of the offering.
Certara, known for its biosimulation technology, has announced the launch of its initial public offering (IPO) of 24,390,000 shares of common stock, with prices expected between $19.00 and $22.00 per share. The offering comprises 14,630,000 shares from Certara and 9,760,000 shares from selling stockholders, who will also give underwriters a 30-day option for an additional 3,658,500 shares. Certara's shares will be listed on Nasdaq under the symbol "CERT." The company will not receive proceeds from shares sold by selling stockholders.